Boehringer Ingelheim BioXcellence

Ingelheim am Rhein, Germany
Biologics mAb Biosimilars Bispecifics Fusion Proteins ADC
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (10) ○ EMA GMP ○ MHRA GMP

Quick Facts: Boehringer Ingelheim BioXcellence

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Ingelheim am Rhein, Germany
Modalities
Biologics, mAb, Biosimilars, Bispecifics, Fusion Proteins, ADC
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesBiologics, mAb, Biosimilars, Bispecifics, Fusion Proteins, ADC
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (6 modalities)

Recent News 10 articles

news Wed, 28 Ma
Our biotech story | BioXcellence - Boehringer Ingelheim
Source →
news Wed, 21 Ma
2025 capacity update | BioXcellence - Boehringer Ingelheim
Source →
news Wed, 20 Au
HGF gene therapy product - Boehringer Ingelheim
Source →
news Wed, 20 Au
Boehringer Ingelheim signs gene therapy manufacturing deal with AnGes - European Pharmaceutical Review
Source →
news Wed, 05 Ma
Boehringer Ingelheim enhances biopharmaceutical contract manufacturing services in China - BioSpectrum Asia
Source →
news Tue, 01 Ju
Sutro Biopharma collaboration first-in-class cell-free capabilities - Boehringer Ingelheim
Source →
news Thu, 21 Au
Boehringer Ingelheim, AnGes collaborate on PAD gene therapy - World Pharmaceutical Frontiers
Source →
news Thu, 21 Au
Boehringer Ingelheim, AnGes sign manufacturing agreement for HGF gene therapy product - Medical Dialogues
Source →
news Thu, 21 Au
Boehringer and AnGes link on drug substance manufacture for PAD - Pharmaceutical Technology
Source →
news Fri, 06 Ju
Boehringer Ingelheim BioXcellence adds fill-finish line to China plant - Fierce Pharma
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics CDMOs → mAb CDMOs → Biosimilars CDMOs → Bispecifics CDMOs → Fusion Proteins CDMOs → ADC CDMOs →

Similar CDMOs

Abzena
San Diego, CA
Biologics, ADC, mAbs, Bispecifics, Fusion Proteins, Recombinant Proteins
Richter BioLogics
Hamburg, Germany
Signal Score: 82.9
Plasmid DNA, Recombinant Proteins, VHH/Nanobodies, Bacterial Vaccines, Biologics
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 91.5
Biologics, mRNA
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score: 84.2
Biologics
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 83.5
AAV, mRNA/LNP, Biologics